Fairvalue-Calculator Fairvalue-Calculator
EN DE

Paxman AB (PXMBF) Fair Value & Analysis

Healthcare · US · Market cap $81.5M

Price$3.50
Fair Value$2.27
Upside-35.1%
Quality95/100
Evidence: Low Range $1.83 – $2.70

Fair value as of: Jun 24, 2026

Analysis

Paxman AB (PXMBF) currently trades at $3.50, while our model-based Fair Value estimate is $2.27 — implying the stock looks roughly 35.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Paxman AB (PXMBF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.27 versus a price of $3.50 — about −35% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PXMBF?
Our 21-model fair value for Paxman AB is $2.27 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.50.
What is the quality score of PXMBF?
Paxman AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.